Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjogren Syndrome: The JOQUER Randomized Clinical Trial
Gottenberg JE
Published in JAMA
Methodology
JOQUER multicentre randomized, double-blind, placebo-controlled trial of hydroxychloroquine in primary Sjogren syndrome, with the primary endpoint a 30% reduction in at least two of three VAS scores for dryness, pain and fatigue at 24 weeks.
Key Findings
Hydroxychloroquine 400 mg/day for 24 weeks did not reduce dryness, pain or fatigue in primary Sjogren syndrome compared with placebo, although some biological markers improved.
Conclusions
Among patients with primary Sjogren syndrome, the use of hydroxychloroquine compared with placebo did not improve symptoms during 24 weeks of treatment.
Limitations
Twenty-four weeks may be too short for hydroxychloroquine, subjective symptom-based primary endpoint, and possible dilution by patients with low baseline systemic activity.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.